How should epistaxis be managed in a patient taking fluoxetine?

Management of Epistaxis in Patients Taking Fluoxetine

Manage epistaxis in patients on fluoxetine using standard epistaxis protocols while recognizing fluoxetine as a bleeding risk factor, but do NOT discontinue the antidepressant without psychiatric consultation. 1, 2

Immediate Management Algorithm

First-Line Treatment (All Patients)

• Lean forward and apply firm sustained compression to the soft part of the nose for at least 5 minutes, continuing for a full 15 minutes if bleeding slows 1
• Clear clots by blowing the nose, then spray 2 sprays of oxymetazoline or phenylephrine into the bleeding nostril
• Continue holding pressure for 5 minutes; may repeat once 1

Assessment of Bleeding Severity

Seek emergency care if:

• Bleeding persists despite 15 minutes of proper compression
• Signs of hemodynamic instability (tachycardia, syncope, orthostatic hypotension)
• Bleeding from both nostrils or mouth
• Patient feels weak or lightheaded 1

The Fluoxetine Factor

Understanding the Risk

Fluoxetine increases bleeding risk through serotonin reuptake inhibition, which impairs platelet function 2, 3. The FDA label explicitly warns about abnormal bleeding when fluoxetine is combined with NSAIDs, aspirin, warfarin, or other anticoagulants 2. While fluoxetine alone can cause epistaxis 4, 3, the risk is substantially higher with concomitant use of antiplatelet or anticoagulant medications.

Critical Medication Management Decision

Do NOT stop fluoxetine without psychiatric consultation 2. The FDA label specifically states: "You should promptly check with the clinician who has prescribed the blood-thinning medication, as these medications are usually given to treat or prevent serious medical problems" 1. While fluoxetine is not a traditional anticoagulant, this principle applies—abrupt discontinuation risks psychiatric decompensation, including emergence of suicidal ideation 2.

Document all medications that impair coagulation or platelet function as this is a guideline recommendation for all epistaxis patients 1.

Advanced Management When First-Line Fails

For Patients on Fluoxetine (with or without other anticoagulants)

• Use resorbable packing preferentially over non-resorbable packing 1—this is a specific guideline recommendation for patients on anticoagulant/antiplatelet medications
• Perform anterior rhinoscopy after clot removal to identify bleeding source 1
• If bleeding site identified: apply topical anesthesia, then use chemical cautery (silver nitrate) or electrocautery restricted to the active bleeding site only 1

If Bleeding Site Cannot Be Identified

• Proceed to nasal packing (resorbable preferred) 1
• Consider nasal endoscopy or refer to otolaryngology for endoscopic evaluation 1

Preventive Measures (Essential Patient Education)

Educate all patients with epistaxis on prevention 1:

• Use nasal saline gel or spray 1-3 times daily for moisturization
• Employ bedside humidifier
• Avoid digital trauma (nose picking) and vigorous nose blowing
• Avoid NSAIDs, aspirin, and other antiplatelet agents when possible 2

Post-Episode Restrictions

For at least one week after cautery or packing:

• No nose blowing
• No strenuous activity or heavy lifting (>10 pounds)
• No cotton or tissues inserted in nose
• Sleep with head slightly elevated 1

Common Pitfalls to Avoid

1. Never discontinue fluoxetine emergently for epistaxis alone—the psychiatric risks outweigh benefits unless bleeding is life-threatening
2. Don't use bilateral cautery—restrict to the actual bleeding site only to avoid septal perforation 1
3. Don't delay evaluation if severe—bleeding >30 minutes over 24 hours, prior hospitalization for epistaxis, or >3 recent episodes warrant prompt assessment 1
4. Don't forget to screen for other bleeding risk factors: Check for concomitant NSAIDs, aspirin, warfarin, other SSRIs, or underlying bleeding disorders 1, 2

Follow-Up Requirements

Document outcome within 30 days or document transition of care if patient required non-resorbable packing, surgery, or arterial intervention 1. This is a specific guideline recommendation to track rebleeding rates and intervention effectiveness.

For recurrent epistaxis on fluoxetine: Consider psychiatric consultation to discuss risk-benefit of continuing SSRI therapy versus switching to an antidepressant with lower bleeding risk, but this decision must balance psychiatric stability against bleeding risk 2, 3.